In order to determine whether the dramatic effects on PC-3 by troglitazone were mediated through activation of PPARγ, the author also evaluated other PPARγ ligands such as BRL49653, 15dPGJ2, ciglitizone, and indomethacin on prostate cancer cell lines. The gene discussed is PPARG; the disease is prostate cancer.